A meta-analysis and systematic review encompassing 82 randomized controlled trials revealed a significant association between DPP-4 inhibitors and an increased risk of cholecystitis, while no such association was found with an increased risk of cholecystolithiasis or other biliary diseases (He et al., 2022a). Here, DPP4 is linked to cholecystolithiasis.